Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 89853413

Next Previous
Drug Profile

JNJ 89853413

Alternative Names: JNJ-3413; JNJ-89853413

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development; Lava Therapeutics
  • Developer Janssen Research & Development
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action CD33 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 14 Jan 2025 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in United Kingdom (unspecified route) (NCT06618001)
  • 14 Jan 2025 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in United Kingdom (unspecified route) (NCT06618001)
  • 14 Jan 2025 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Spain, Canada (unspecified route) (NCT06618001, EudraCT2024-513199-16-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top